AR080361A1 - Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) - Google Patents
Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)Info
- Publication number
- AR080361A1 AR080361A1 ARP110100349A ARP110100349A AR080361A1 AR 080361 A1 AR080361 A1 AR 080361A1 AR P110100349 A ARP110100349 A AR P110100349A AR P110100349 A ARP110100349 A AR P110100349A AR 080361 A1 AR080361 A1 AR 080361A1
- Authority
- AR
- Argentina
- Prior art keywords
- alk
- cancer
- anaplasic
- canceres
- lymphoma
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title 1
- 238000011156 evaluation Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33746510P | 2010-02-04 | 2010-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080361A1 true AR080361A1 (es) | 2012-04-04 |
Family
ID=44355876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100349A AR080361A1 (es) | 2010-02-04 | 2011-02-02 | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9018230B2 (enExample) |
| EP (1) | EP2531858B1 (enExample) |
| JP (1) | JP5937017B2 (enExample) |
| KR (1) | KR101843967B1 (enExample) |
| CN (2) | CN103937877B (enExample) |
| AR (1) | AR080361A1 (enExample) |
| AU (1) | AU2011212165B2 (enExample) |
| BR (1) | BR112012019215A2 (enExample) |
| CA (1) | CA2786974C (enExample) |
| ES (1) | ES2660149T3 (enExample) |
| MX (1) | MX336498B (enExample) |
| NZ (1) | NZ601606A (enExample) |
| RU (1) | RU2589834C2 (enExample) |
| SG (1) | SG182766A1 (enExample) |
| TW (1) | TWI518325B (enExample) |
| WO (1) | WO2011095894A2 (enExample) |
| ZA (1) | ZA201205831B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| WO2012019132A2 (en) * | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| JP6205216B2 (ja) * | 2012-09-24 | 2017-09-27 | アークレイ株式会社 | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット |
| US9428812B2 (en) * | 2014-04-28 | 2016-08-30 | Insight Genetics, Inc. | Kit comprising primers for amplifying ALK kinase domain nucleic acids |
| EP3186284B1 (en) * | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| US20170349953A1 (en) * | 2016-06-01 | 2017-12-07 | Roche Sequencing Solutions, Inc. | Novel mutations in anaplastic lymphoma kinase predicting response to alk inhibitor therapy in lung cancer patients |
| KR101872624B1 (ko) * | 2016-12-27 | 2018-06-28 | (주) 바이오인프라생명과학 | Alk 표적 치료제에 대한 폐암의 치료 반응성을 예측하는 방법 |
| CN107828823A (zh) * | 2017-09-29 | 2018-03-23 | 暨南大学 | 一种评价eml4‑alk抑制剂对肺癌治疗效果的方法 |
| RU2717309C2 (ru) * | 2018-08-01 | 2020-03-20 | Общество с ограниченной ответственностью "ОНКОДИАГНОСТИКА АТЛАС" | Способ определения микросателлитной нестабильности |
| KR102890173B1 (ko) | 2018-11-01 | 2025-11-21 | 일루미나, 인코포레이티드 | 체세포 변이 검출을 위한 방법 및 조성물 |
| IL297442A (en) | 2020-04-22 | 2022-12-01 | Iovance Biotherapeutics Inc | Systems and methods for coordinating production of cells for patient-specific immunotherapy |
| WO2024017352A1 (zh) * | 2022-07-22 | 2024-01-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
| US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| JP2955759B2 (ja) | 1988-07-20 | 1999-10-04 | セゲブ・ダイアグノスティックス・インコーポレイテッド | 核酸配列を増幅及び検出する方法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| KR0148265B1 (ko) | 1988-12-16 | 1998-10-15 | 에프.지이.엠 헤르만스 | 자가-지속 서열 복제 시스템 |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| IE66597B1 (en) | 1989-05-10 | 1996-01-24 | Akzo Nv | Method for the synthesis of ribonucleic acid (RNA) |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| DE69033493D1 (de) | 1989-07-25 | 2004-08-12 | Cell Genesys Inc | Homologe rekombination für universelle donorzellen und chimerische säugetierzellen |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| IL98764A0 (en) | 1990-07-10 | 1992-07-15 | Smithkline Beecham Corp | Oxamides |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6277569B1 (en) | 1990-09-20 | 2001-08-21 | Vysis, Inc. | Methods for multiple direct label probe detection of multiple chromosomes or regions thereof by in situ hybridization |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2087413A1 (en) | 1992-01-17 | 1993-07-18 | Joseph R. Lakowicz | Fluorescent energy transfer immunoassay |
| DE69322266T2 (de) | 1992-04-03 | 1999-06-02 | Perkin-Elmer Corp., Foster City, Calif. | Proben zusammensetzung und verfahren |
| FR2690691B1 (fr) | 1992-04-29 | 1999-02-12 | Bio Merieux | Procede d'amplification d'arn necessitant une seule etape de manipulation. |
| DE69433811T2 (de) | 1993-01-07 | 2005-06-23 | Sequenom, Inc., San Diego | Dns - sequenzierung durch massenspektronomie |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| DE69430909T2 (de) | 1993-03-19 | 2003-02-27 | Sequenom, Inc. | Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5571676A (en) | 1995-06-07 | 1996-11-05 | Ig Laboratories, Inc. | Method for mismatch-directed in vitro DNA sequencing |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US6261775B1 (en) | 1999-04-09 | 2001-07-17 | The Regents Of The University Of California | Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma |
| CA2379264A1 (en) * | 1999-07-09 | 2001-01-18 | The Burnham Institute | A method for determining the prognosis of cancer patients by measuring levels of bag expression |
| PL1713806T3 (pl) * | 2004-02-14 | 2013-09-30 | Irm Llc | Związki i kompozycje jako inhibitory kinaz białkowych |
| ES2561406T3 (es) * | 2006-04-14 | 2016-02-26 | Cell Signaling Technology, Inc. | Defectos de genes y quinasa ALK mutante en tumores sólidos humanos |
| JP5562640B2 (ja) | 2007-04-13 | 2014-07-30 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| WO2009103061A2 (en) | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| JP2011513427A (ja) | 2008-03-06 | 2011-04-28 | ジェネンテック， インコーポレイテッド | ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法 |
| EP3133167B1 (en) * | 2009-05-15 | 2018-09-12 | Insight Genetics, Inc. | Methods relating to fusions of alk for diagnosing cancer |
| US9031642B2 (en) | 2013-02-21 | 2015-05-12 | Medtronic, Inc. | Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms |
-
2011
- 2011-02-01 TW TW100103831A patent/TWI518325B/zh not_active IP Right Cessation
- 2011-02-02 AR ARP110100349A patent/AR080361A1/es active IP Right Grant
- 2011-02-04 MX MX2012008914A patent/MX336498B/es unknown
- 2011-02-04 ES ES11739469.2T patent/ES2660149T3/es active Active
- 2011-02-04 CA CA2786974A patent/CA2786974C/en active Active
- 2011-02-04 CN CN201410061691.6A patent/CN103937877B/zh not_active Expired - Fee Related
- 2011-02-04 BR BR112012019215A patent/BR112012019215A2/pt not_active IP Right Cessation
- 2011-02-04 RU RU2012133318/15A patent/RU2589834C2/ru active
- 2011-02-04 SG SG2012055885A patent/SG182766A1/en unknown
- 2011-02-04 WO PCT/IB2011/000382 patent/WO2011095894A2/en not_active Ceased
- 2011-02-04 KR KR1020127022771A patent/KR101843967B1/ko not_active Expired - Fee Related
- 2011-02-04 US US13/576,508 patent/US9018230B2/en active Active
- 2011-02-04 CN CN2011800058134A patent/CN102844664A/zh active Pending
- 2011-02-04 NZ NZ601606A patent/NZ601606A/en not_active IP Right Cessation
- 2011-02-04 JP JP2012551704A patent/JP5937017B2/ja not_active Expired - Fee Related
- 2011-02-04 AU AU2011212165A patent/AU2011212165B2/en not_active Ceased
- 2011-02-04 EP EP11739469.2A patent/EP2531858B1/en not_active Not-in-force
-
2012
- 2012-08-02 ZA ZA2012/05831A patent/ZA201205831B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011212165B2 (en) | 2016-03-03 |
| AU2011212165A1 (en) | 2012-09-20 |
| CN103937877B (zh) | 2016-09-28 |
| WO2011095894A3 (en) | 2012-03-01 |
| TWI518325B (zh) | 2016-01-21 |
| SG182766A1 (en) | 2012-08-30 |
| CA2786974A1 (en) | 2011-08-11 |
| BR112012019215A2 (pt) | 2016-10-25 |
| EP2531858A4 (en) | 2013-08-07 |
| HK1197922A1 (zh) | 2015-02-27 |
| JP5937017B2 (ja) | 2016-06-22 |
| ZA201205831B (en) | 2013-05-29 |
| WO2011095894A2 (en) | 2011-08-11 |
| CN103937877A (zh) | 2014-07-23 |
| CN102844664A (zh) | 2012-12-26 |
| NZ601606A (en) | 2014-06-27 |
| US20130203810A1 (en) | 2013-08-08 |
| RU2589834C2 (ru) | 2016-07-10 |
| JP2013518579A (ja) | 2013-05-23 |
| MX2012008914A (es) | 2012-11-30 |
| RU2012133318A (ru) | 2014-03-10 |
| ES2660149T3 (es) | 2018-03-21 |
| EP2531858B1 (en) | 2018-01-10 |
| KR20120130329A (ko) | 2012-11-30 |
| MX336498B (es) | 2016-01-21 |
| US9018230B2 (en) | 2015-04-28 |
| EP2531858A2 (en) | 2012-12-12 |
| CA2786974C (en) | 2018-05-01 |
| TW201144807A (en) | 2011-12-16 |
| KR101843967B1 (ko) | 2018-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BR112013010015A2 (pt) | aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| EA201400491A1 (ru) | Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| MX378788B (es) | Kits y ensayos de diagnóstico para la detección del receptor 1 de folato. | |
| CO2019008390A2 (es) | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. | |
| MX382410B (es) | Determinación de niveles de glicosaminoglicanos mediante espectrometría de masas. | |
| EA201490946A1 (ru) | Способ количественной оценки лечения рака | |
| EP3159695A3 (en) | Methods for diagnosing pancreatic cancer | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| FR3060755B1 (fr) | Methode de diagnostic d'une peau presentant des signes de secheresse | |
| BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia | |
| MX2021009528A (es) | Prueba de diagnostico basada en fragmento de rgma. | |
| BR112015021507A2 (pt) | métodos e composições para o diagnóstico de pré-eclampsia | |
| BR112015029852A2 (pt) | método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9 | |
| BR112014015424A2 (pt) | detecção de células derivadas de tecido do cordão umbilical humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |